Phase II Trial of Pembrolizumab, Ipilimumab, and Aspirin in Melanoma: Clinical Outcomes and Translational Predictors of Response

Investigators conducted the first prospective phase II single-arm study of combination high-dose aspirin with standard of care ipilimumab and pembrolizumab for patients with advanced/metastatic melanoma to determine safety and efficacy of COX inhibition when combined with immune checkpoint inhibitors.